|
|
 |
|
Viewing report
|
|
|
|
Acute Leukemias - Persistent Unmet Needs Confer Significant Commercial Opportunity
Datamonitor, April 2006, Pages: 205
While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.
Scope of this title:
- Overview of acute leukemias including epidemiology, etiology, disease classification and prognostic variables.
- Current treatment controversies and novel therapies in the developmental pipeline.
- Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development.
- Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders from the US and Europe.
Highlights of this title:
For the innovators of novel and efficacious pharmacotherapy, commercial opportunities within the acute leukemia market are rife. Developers can exploit the high unmet needs that currently prevail in the acute leukemia market by using accelerated approval pathways to expedite market access and drive commercialization
Future drug development approaches will respond to the increased identification of gene mutations and their ensuing proteonomic manifestations. This approach is more likely to address the heterogeneity of acute leukemia and will contribute to the increasing trend of risk-stratified treatment approaches.
Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.
Reasons to order your copy:
- Identify the areas of unmet need and clinical controversy in acute leukemia treatment.
- Understand how advancements in acute leukemia prognostication and risk-stratification may shift future treatment paradigms
- Assess opportunities and risks for innovative treatments targeting the acute leukemias.
Customers who bought this item also bought
Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets
Chronic Leukemias - Curative Intent Raises The Bar
Acute Stroke - Considerable Unmet Need is Balanced by Substantial Commercial Risk
Niche Cancers 2001: Acute Myeloid Leukemia
Acute Myeloid Leukemia: Cytarabine Here to Stay
Antithrombotics in Acute Ischemic Stroke - The Clot Thickens
Sinusitis: Unmet need and opportunity
Side Effects of Male Cancers - Better Survival and Growing Social Acceptance of Impotence and Urinary Incontinence Equates to New Opportunities for Drug Therapies
|
|
|
|
